A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects with Pain Associated with Diabetic Peripheral Neuropathy
Phase 3 Study Evaluating Suzetrigine for Pain Caused by Diabetic Peripheral Neuropathy
Sponsor: Vertex Pharmaceuticals Incorporated
Enrolling: Male and Female Patients
IRB Number: AAAV3851
U.S. Govt. ID: NCT06628908
Contact: Jorge Cabrera, CRC: 212-305-7462 / jec2273@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety, tolerability and effectiveness of VX-548 in participants with pain due to Diabetic Peripheral Neuropathy (DPN). To be in this study you must have DPN and be 18 through 80 years of age, inclusive, with presence of bilateral pain in lower extremities due to DPN for at least 1 year.
Investigator
Thomas Brannagan, MD
Do You Qualify?
Are you between 18 and 80 years old? Yes No
Have you been diagnosed with diabetes? Yes No
Do you have a history of major depression in the past 12 months? Yes No
Do you have pain in both legs? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Jorge Cabrera, CRC
jec2273@cumc.columbia.edu
212-305-7462
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE